BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 6481707)

  • 1. Pill formulations and their effect on lipid and carbohydrate metabolism.
    Brooks PG
    J Reprod Med; 1984 Jul; 29(7 Suppl):539-46. PubMed ID: 6481707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic risks of oral contraception].
    Monier L
    Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral contraceptives and metabolic changes].
    Lara Ricalde R; Aznar Ramos R
    Ginecol Obstet Mex; 1986 Aug; 54():212-5. PubMed ID: 3781292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U; Lambotte R
    Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives.
    Shearman RP
    Aust Fam Physician; 1984 Sep; 13(9):685-91. PubMed ID: 6508652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerotic risk factors in cardiovascular disease.
    LaRosa JC
    J Reprod Med; 1986 Sep; 31(9 Suppl):906-12. PubMed ID: 3772910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives and coronary heart disease.
    Wynn V
    J Reprod Med; 1991 Mar; 36(3 Suppl):219-25. PubMed ID: 2046075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the metabolic effects of steroidal contraceptives.
    Sondheimer SJ
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of oral contraceptives: a review.
    Stubblefield PG
    Int J Fertil; 1989; 34 Suppl():40-9. PubMed ID: 2576258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
    Bakir R; Hilliquin P
    Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OC practice guidelines: minimizing side effects.
    Darney PD
    Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive.
    Batzer FR
    J Reprod Med; 1984 Jul; 29(7 Suppl):503-12. PubMed ID: 6237195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.